<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Rev Paul Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">Rev Paul Pediatr</journal-id>
<journal-id journal-id-type="publisher-id">rpp</journal-id>
<journal-title-group>
<journal-title>Revista Paulista de Pediatria</journal-title>
</journal-title-group>
<issn pub-type="ppub">0103-0582</issn>
<issn pub-type="epub">1984-0462</issn>
<publisher>
<publisher-name>Sociedade de Pediatria de São Paulo</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30365815</article-id>
<article-id pub-id-type="pmc">6202899</article-id>
<article-id pub-id-type="doi">10.1590/1984-0462/;2018;36;3;00003</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>PRADER-WILLI SYNDROME: WHAT IS THE GENERAL PEDIATRICIAN SUPPOSED TO
DO? - A REVIEW</article-title>
<trans-title-group xml:lang="pt">
<trans-title>SÍNDROME DE PRADER WILLI: O QUE O PEDIATRA GERAL DEVE FAZER - UMA
REVISÃO</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Passone</surname>
<given-names>Caroline Buff Gouveia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="c1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pasqualucci</surname>
<given-names>Paula Lage</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Franco</surname>
<given-names>Ruth Rocha</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ito</surname>
<given-names>Simone Sakura</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mattar</surname>
<given-names>Larissa Baldini Farjalla</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Koiffmann</surname>
<given-names>Celia Priszkulnik</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soster</surname>
<given-names>Leticia Azevedo</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carneiro</surname>
<given-names>Jorge David Aivazoglou</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cabral</surname>
<given-names>Hamilton</given-names>
<suffix>Menezes-Filho</suffix>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Damiani</surname>
<given-names>Durval</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>a</label>Instituto da Criança, São Paulo, SP, Brasil.</aff>
<aff id="aff2">
<label>b</label>Instituto de Ciências Biomédicas, São Paulo, SP, Brasil.</aff>
<aff id="aff3">
<label>c</label>Instituto Central do Hospital das Clinicas, São Paulo, SP,
Brasil.</aff>
<author-notes>
<corresp id="c1"><label>*</label>Corresponding author. E-mail:
<email>carol.passone@gmail.com</email> (C.B.G. Passone).</corresp>
<fn fn-type="COI-statement" id="fn2">
<p>Conflict of interests: The authors declare no conflict of interests.</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<season>Jul-Sep</season>
<year>2018</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<season>Jul-Sep</season>
<year>2018</year>
</pub-date>
<volume>36</volume>
<issue>3</issue>
<fpage>345</fpage>
<lpage>352</lpage>
<history>
<date date-type="received">
<day>02</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="pub">
<day>12</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p>
</license>
</permissions>
<abstract>
<title>ABSTRACT</title>
<sec>
<title>Objective:</title>
<p> To carry out a review about Prader-Willi Syndrome based on the most recent
data about the subject and to give recommendation for the general
pediatricians for early diagnoses and follow-up. </p>
</sec>
<sec>
<title>Data sources:</title>
<p> Scientific articles in the PubMed and SciELO databases. The research was not
limited to a specific time period and included all articles in such
databases.</p>
</sec>
<sec>
<title>Data synthesis:</title>
<p> The Prader-Willi Syndrome (PWS) is a rare genetic disorder resulting from
the loss of imprinted gene expression within the paternal chromosome
15q11-q13. PWS is characterized by endocrine abnormalities, such as growth
hormone (GH) deficiency, obesity, central adrenal insufficiency,
hypothyroidism, hypogonadism and complex behavioral and intellectual
difficulties. PWS individuals also may present other comorbidities, such as
sleep disorders, scoliosis, constipation, dental issues and coagulation
disorders. The follow-up protocol of the Children’s Institute at
Universidade de São Paulo is based on four main pillars: diet, exercise,
recombinant human growth hormone (rhGH) therapy and behavioral and cognitive
issues. The diet must include a caloric restriction of 900 kcal/day,
according to the Prader-Willi Eating Pyramid and exercise plan is focused on
daily aerobic exercises and postural therapy. The rhGH therapy is highly
recommended by the international scientific literature and must be started
as soon as the diagnostic is made. The management of behavioral issues is
based on strategies to establish routine and rules. </p>
</sec>
<sec>
<title>Conclusions:</title>
<p> If the general pediatrician becomes more familiar with PWS, the diagnosis
and treatment will start earlier, which is essential to improve the quality
of life and care for these individuals.</p>
</sec>
</abstract>
<trans-abstract xml:lang="pt">
<title>RESUMO</title>
<sec>
<title>Objetivo:</title>
<p> Realizar uma revisão sobre a Síndrome de Prader-Willi (SPW) com base nas
publicações mais recentes e fornecer recomendações ao pediatra geral para
diagnóstico precoce e seguimento.</p>
</sec>
<sec>
<title>Fonte de dados:</title>
<p> Artigos publicados nas bases Pubmed e SciELO. A pesquisa não foi limitada a
um período e incluiu todos os artigos das bases de dados.</p>
</sec>
<sec>
<title>Síntese dos dados:</title>
<p> A SPW é uma síndrome genética rara, resultante da perda do imprinting gênico
expresso no cromossomo paterno 15q11-q13, sendo caracterizada por alterações
endocrinológicas, como deficiência de hormônio de crescimento, obesidade,
insuficiência adrenal central, hipotireoidismo, hipogonadismo, além de
alterações comportamentais e déficit intelectual. Há outras comorbidades
associadas, como distúrbios de sono, escoliose, constipação, problemas
dentários e alterações de coagulação. O protocolo de seguimento da SPW do
Instituto da Criança da Universidade de São Paulo se baseia em quarto
pilares principais: dieta, exercício físico, terapia com hormônio de
crescimento humano recombinante (rhGH) e manejo comportamental e cognitivo.
A dieta deve ser restrita a 900 kcal/dia, de acordo com a Pirâmide Alimentar
do Prader-Willi, e o exercício físico deve ser diário, aeróbico e postural.
A terapia com rhGH é fortemente recomendada pela literatura científica
internacional e deve ser iniciada assim que for realizado o diagnóstico da
síndrome. O manejo do comportamento é realizado com estratégias para
estabelecer rotina e regras.</p>
</sec>
<sec>
<title>Conclusões:</title>
<p> Se a SPW se tornar mais familiar ao pediatra geral, o diagnóstico e o
tratamento começarão mais precocemente, o que irá melhorar a qualidade de
vida e os cuidados desses pacientes.</p>
</sec>
</trans-abstract>
<kwd-group>
<title>Keywords:</title>
<kwd>Prader-Willi Syndrome</kwd>
<kwd>Growth hormone</kwd>
<kwd>Behavior</kwd>
<kwd>Diet</kwd>
<kwd>Treatment</kwd>
</kwd-group>
<kwd-group xml:lang="pt">
<title>Palavras-chave:</title>
<kwd>Síndrome de Prader-Willi</kwd>
<kwd>Hormônio de crescimento</kwd>
<kwd>Comportamento</kwd>
<kwd>Dieta</kwd>
<kwd>Tratamento</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="4"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="44"></ref-count>
<page-count count="08"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>The Prader-Willi Syndrome (PWS) is a rare genetic disorder resulting from the loss of
gene expression within the paternal chromosome 15q11-q13. PWS has a prevalence rate
of 1/10-30,000 and is characterized by endocrine abnormalities due to
hypothalamic-pituitary insufficiency and complex physical, behavioral and
intellectual difficulties.<xref ref-type="bibr" rid="B1">
<sup>1</sup>
</xref>
</p>
<p>Nowadays, most developing countries can reach an early diagnosis, at around 8.6 weeks
of life,<xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref> however, even in centers of mean reference of the diagnosis, it happens at
3.9 years of age. The purpose of clinical diagnostic criteria has changed in the
last decades.<xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref> In 1993, when genetic tests were still very limited, a consensus was
established that served as a guideline for the diagnosis and was known as the
criteria of HOLM.<xref ref-type="bibr" rid="B4">
<sup>4</sup>
</xref> Gunay-Aaygun et al., in 2001, aiming at an early diagnosis, proposed
sufficient features of PWS, which should prompt DNA testing: hypotonia with poor
sucking under 2 years of age, hypotonia with history of poor sucking and global
developmental delay between 2-6 years of age, and hyperphagia and cognitive
impairment after the age of 6 years.<xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref> As the disease aspects may be non-specific or only appear over time,
clinical criteria may often fail to identify PWS cases. However, in the last
decades, molecular genetic tests became available for the definitive diagnosis of
PWS, and clinical criteria were recognized as an initial screening for the
indication of the genetic test.<xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref>
</p>
<p>Three different genetic mechanisms can lead to PWS: paternal deletion within
chromosome region 15q11-q13, which occurs in approximately 70% of the cases.
Maternal uniparental disomy of chromosome 15 (UPD15), occurring in approximately 25%
of the affected individuals, whereas about 2% of PWS patients have biparental
inheritance of chromosome 15, but show abnormal methylation pattern and gene
expression. These patients have a defect in the imprinting center. The recurrence
risk in deletion and UPD cases is less than 1%, whereas for families in which the
patient presents with defect in imprinting, the risk can be as high as 50%.<xref ref-type="bibr" rid="B15">
<sup>5</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B6">
<sup>6</sup>
</xref> Therefore, the identification of the genetic mechanism involved in each
patient is a requirement for the genetic counseling and depends on the efficiency
and reliability of the genetic test.</p>
<p>An efficient strategy for the routine diagnosis of PWS patients consists of
methylation analysis, which allows the diagnosis of 99% of PWS patients, and does
not require parental samples. In patients with a normal methylation pattern and
normal chromosomes, a clinical reassessment is recommended to determine whether
additional DNA investigations are indicated.</p>
<p>PWS is the main genetic cause of obesity in children, and the early approach can
improve quality of care, which may give these individuals a better perspective of
life.</p>
</sec>
<sec>
<title>NATURAL HISTORY AND MANIFESTATIONS</title>
<p>The weight, length and body mass index of infants with PWS is often in the normal
range at birth, however, they evolve with hypotonia associated with suction and
feeding impairments, besides growth impairment.</p>
<p>According to Miller, there are seven different nutritional phases to which
individuals with PWS typically progress. At the pre-natal phase (phase 0), there are
reduced fetal movements and growth restriction. From birth up to 9 months of age
(phase 1a) the infant is hypotonic, has feeding impairment and reduced appetite.
After this period, PWS patients start gaining weight progressively. In spite of a
normal caloric intake, they gain weight due to reduced metabolism (phase 1b: 9
months-2 years/phase 2a:2-4.5 years). After 4.5 years (phase 2b), the weight
increase is associated with increased interest in food, but not hyperphagia. Around
the age of 8 years, hyperphagia is established, characterized by food seeking and
lack of satiety. Some of the individuals with PWS progress to phase 4 in adult life,
when there is some leve of satiety.<xref ref-type="bibr" rid="B7">
<sup>7</sup>
</xref>
</p>
<p>During early childhood, there is delayed motor and language development, with
milestones achieved at about double the normal age. Intellectual and/or learning
disabilities are variable and generally evident by the time the child reaches school
age.<xref ref-type="bibr" rid="B8">
<sup>8</sup>
</xref>
</p>
</sec>
<sec>
<title>ENDOCRINOPATHIES</title>
<p>Individuals with PWS can present with several different endocrine disorders, most of
them caused by hypothalamic-pituitary insufficiency.</p>
<sec>
<title>rhGH deficiency</title>
<p>The insulin-like growth factor 1 (IGF1) and the insulin-like growth factor
binding protein 3 (IGFBP3) are low in PWS, and GH deficiency occurs in 40-100%
of children.<xref ref-type="bibr" rid="B9">
<sup>9</sup>
</xref>
</p>
<p>Growth hormone is an anabolic agent that increases lean body mass (LBM) and
decreases fat mass in a range of conditions. It is recommended that rhGH therapy
be discussed at the time of diagnosis and GH testing is not mandatory before the
beginning of GH treatment.<xref ref-type="bibr" rid="B7">
<sup>7</sup>
</xref> One of the most important reasons for treating PWS children with rhGH is
to improve their body composition, increasing LBM and reducing fat mass, once
the natural history of PWS shows increasing progressive fat mass with age.<xref ref-type="bibr" rid="B10">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B11">
<sup>11</sup>
</xref>
</p>
<p>The rhGH therapy in combination with a healthy lifestyle makes it possible to
counteract the clinical course of PWS, preventing obesity, a major threat to
these patients.</p>
<p>Another important gain from the use of rhGH therapy is the positive effect on
markers of development, such as verbal IQs, adaptive communication, cognitive
skills and language.<xref ref-type="bibr" rid="B12">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B13">
<sup>13</sup>
</xref> Children who began treatment before 12 months of age had higher
nonverbal and higher composite IQs than children who began treatment between 1
and 5 years of age.<xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>
</p>
<p>The use of rhGH has not demonstrated any adverse effects on glucose parameters,
lipid profile, bone mineral density or blood pressure, although insulin levels,
HOMA-IR and IGF-1 may increase, as expected, during therapy. There was not a
clear correlation between rhGH therapy and the development of scoliosis, but a
close follow-up is recommended for its high prevalence in PWS, especially during
puberty.<xref ref-type="bibr" rid="B11">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B12">
<sup>12</sup>
</xref>
</p>
<p>Growth hormone replacement in children with PWS has well-defined benefits and
risks, although data are limited to adults with PWS.<xref ref-type="bibr" rid="B15">
<sup>15</sup>
</xref> The reports on rhGH treatment in adults with PWS indicate improved body
composition, with increased LBM, reduced total body fat, subcutaneous adiposity
and visceral fat, but with minor increase in fasting glucose after 12 months of
treatment.<xref ref-type="bibr" rid="B16">
<sup>16</sup>
</xref>
</p>
<p>Exclusion criteria for starting rhGH therapy in patients with PWS include severe
obesity, uncontrolled diabetes, untreated severe obstructive sleep apnea, active
cancer, and active psychosis. Infants and children with PWS should start on a
daily dose of 0.5 mg/m<sup>2</sup>/day, with subsequent adjustments toward 1.0
mg/m<sup>2</sup>/day every 3-6 months, according to clinical response.
Adults with PWS should receive a starting dose of 0.1-0.2 mg/day. Subsequent
dose titration should be based on clinical response, age, and sex-appropriate
IGF-I levels in the 0 to +2 SDS range.<xref ref-type="bibr" rid="B17">
<sup>17</sup>
</xref>
</p>
</sec>
<sec>
<title>Central Adrenal Insufficiency</title>
<p>In a study with 25 randomly selected PWS children performed by van Wijingaarden
et al., 60% of the children presented with central adrenal insufficiency,
although they had normal morning salivary cortisol levels. It suggests that
adrenal insufficiency becomes apparent only during stressful conditions.
Therefore, it is recommended to monitor cortisol levels before starting the rhGH
treatment and assess them in situations of severe comorbidity. Van Wijingaarden
et al. also suggested that hydrocortisone should be used during the acute phase
of severe diseases that affect the patient (<xref ref-type="table" rid="t3">Table 1</xref>)<xref ref-type="bibr" rid="B18">
<sup>18</sup>
</xref>.</p>
<p>
<table-wrap id="t3" orientation="portrait" position="float"><label>Table 1:</label><caption><title>Health Maintenance Timeline for Children with Prader-Willi
Syndrome.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Lab Follow-up/Intervention</th><th align="center" colspan="1" rowspan="1">Timing</th><th align="center" colspan="1" rowspan="1">Recommendations</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">IGF-1 IGFBP3</td><td align="center" colspan="1" rowspan="1">At 3 months and after starting rhGH every 4-6
months </td><td align="center" colspan="1" rowspan="1">Maintain levels between +1 and +2 SD of IGF-1
during GH use</td></tr><tr><td align="left" colspan="1" rowspan="1">TSH Free T4</td><td align="center" colspan="1" rowspan="1">Every 12 months</td><td align="center" colspan="1" rowspan="1">With abnormal levels, conduct stricter
follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">Glucose profile (glucose, Insulin)</td><td align="center" colspan="1" rowspan="1">Every 4-6 months</td><td align="center" colspan="1" rowspan="1">Consider metformin in females. Consider Hb1Ac
and OGTT if insulin resistance</td></tr><tr><td align="left" colspan="1" rowspan="3">ACTH and cortisol levels</td><td align="center" colspan="1" rowspan="3">Before starting rhGH therapy and
in other situations of severe comorbidity</td><td align="center" colspan="1" rowspan="1">All patients are advised to use
corticosteroids for stressful conditions (during surgery or
systemic disease):</td></tr><tr><td align="center" colspan="1" rowspan="1">Attack with 50 mg/m<sup>2</sup> of
hydrocortisone</td></tr><tr><td align="center" colspan="1" rowspan="1">Maintenance: 100 mg/m<sup>2</sup> /day of
hydrocortisone </td></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol and triglycerides</td><td align="center" colspan="1" rowspan="1">Every 6-12 months</td><td align="center" colspan="1" rowspan="1">Depending on weight, levels and diet</td></tr><tr><td align="left" colspan="1" rowspan="1">Polysomnography </td><td align="center" colspan="1" rowspan="1">Every 6-12 months</td><td align="center" colspan="1" rowspan="1">Also, with abnormal weight gain, snoring,
appearance of daytime symptoms or poor school
performance</td></tr><tr><td align="left" colspan="1" rowspan="1">Orthopedic Evaluation</td><td align="center" colspan="1" rowspan="1">Once a year</td><td align="center" colspan="1" rowspan="1">Check for scoliosis</td></tr><tr><td align="left" colspan="1" rowspan="1">Dental Check-Up</td><td align="center" colspan="1" rowspan="1">Every 6 months</td><td align="center" colspan="1" rowspan="1">Start teaching tooth care at a young age.
Teeth should be washed twice a day, beginning as soon as the
first tooth appear. </td></tr></tbody></table></table-wrap>
</p>
</sec>
<sec>
<title>Hypothyroidism</title>
<p>Hypothyroidism, particularly of central origin, is present in PWS. It has been
documented in up to 25% of the individuals with PWS.</p>
<p>In general, thyroid function is normal at birth and treatment should not be
routinely prescribed to young people with PWS. It is important to perform
thyroid function screening regularly, since hypothyroidism can contribute with
delayed psychomotor development, impaired linear growth during childhood and
increasing fat mass and hypotonia.<xref ref-type="bibr" rid="B19">
<sup>19</sup>
</xref>
</p>
</sec>
<sec>
<title>Hypogonadism </title>
<p>Hypogonadism is highly frequent among PWS patients, and its presentation is
extremely variable. It is usually seen as genital hypoplasia, delayed puberty,
incomplete pubertal development and infertility, but early puberty and premature
pubarche may occur as well.</p>
<p>The etiology of hypogonadism in PWS is heterogeneous and is due to a combination
of hypothalamic and gonadal primary dysfunction, besides the fact that sexual
hormones (testosterone and estradiol) are usually below normal range.</p>
<p>Even though the benefits of sex hormone replacement in hypogonadism are well
known, there are few reports in the literature and there is still no consensus
about when or how it should be done.<xref ref-type="bibr" rid="B20">
<sup>20</sup>
</xref>
</p>
</sec>
<sec>
<title>Obesity</title>
<p>Obesity and its complications are the major causes of morbidity and mortality in
individuals with PWS. There is some evidence to suggest a hypothalamic basis and
an abnormal neural response to food intake.<xref ref-type="bibr" rid="B21">
<sup>21</sup>
</xref> In PWS, the response os satiety is delayed, reduced or absent to
food.<xref ref-type="bibr" rid="B22">
<sup>22</sup>
</xref> The etiology of obesity is mostly attributed to a low basal metabolism
and an elevated circulating ghrelin level than to the increased caloric
intake.<xref ref-type="bibr" rid="B23">
<sup>23</sup>
</xref>
</p>
<p>The maximal weight in PWS patients frequently occurs in late adolescence and
early adulthood. For these patients, uncertainty and opportunity related to food
consumption are a constant source of stress. Thus, they show signs of anxiety
and other stress symptoms when they are responsible for their own food
regulation. The main implication of these findings for the management of PWS is
that the supervision of the food environment is critically important. Early
counseling, caloric restriction and dietary recommendations can help keeping
normal weight-for-height ratio.<xref ref-type="bibr" rid="B7">
<sup>7</sup>
</xref>
</p>
<p>Up to now, pharmacologic intervention with appetite suppressants (sibutramine),
anti-absorption agents (orlistat), topiramate or glucagon-like peptide 1 (GLP-1)
receptor agonist have been ineffective in patients with PWS.<xref ref-type="bibr" rid="B24">
<sup>24</sup>
</xref>
</p>
<p>A small series of cases reported short-term success with bariatric surgery in
PWS. The results suggest there is little justification for subjecting PWS
patients to the potential risks of surgical interventions, besides the risk of
gastric rupture. The best recommendation for weight control in cases of severe
obesity includes the use of supervised energy reduction diets with
vitamin/mineral supplementation, restricted access to food, and a daily exercise
regimen.<xref ref-type="bibr" rid="B25">
<sup>25</sup>
</xref>
</p>
</sec>
<sec>
<title>Impaired glucose tolerance and diabetes mellitus</title>
<p>Up to 25% of adults with PWS presented type 2 diabetes.<xref ref-type="bibr" rid="B26">
<sup>26</sup>
</xref> In a multicenter study based on 274 PWS patients, altered glucose was
detected in 24.4% of the patients and was significantly correlated to age, body
mass index (BMI) and HOMA-IR. This study shows the strong correlation between
development of altered glucose metabolism, obesity and aging.<xref ref-type="bibr" rid="B27">
<sup>27</sup>
</xref>
</p>
</sec>
</sec>
<sec>
<title>BEHAVIORAL ISSUES AND COGNITION</title>
<p>Individuals with PWS present with impaired cognitive, communication and social
skills. They may show a compulsive, manipulative and controlling behavior including
stubbornness, episodes of temper tantrums and difficulties in changing routines.
They also present a mild intellectual disability, with a mean IQ of approximately
65-70.<xref ref-type="bibr" rid="B28">
<sup>28</sup>
</xref>
</p>
<p>A study comparing magnetic resonance imaging brain scan and cognitive skills showed
reduction in cortical gyrus, mainly in the frontal, temporal and parietal lobes,
irrespective of the genetic subtype. There was strong correlation between the
alterations of these brain regions and the verbal impairment and lower IQ score in
the PWS group. Frontal-parietal cortical areas are implicated in cognitive function,
such as memory, attention regulation and language.<xref ref-type="bibr" rid="B29">
<sup>29</sup>
</xref>
</p>
<p>PWS carriers are prone to more severe behavior problems, and as many as 85% show
clinically elevated scores on standardized behavioral evaluation questionnaires.
They present with high rates of obsessive-compulsive symptoms, which may express as
excessive hoarding, repetitive rituals, talking too much and skin picking. Of these,
skin picking seems to be the most prevalent and starts in early childhood.<xref ref-type="bibr" rid="B30">
<sup>30</sup>
</xref> Aggressive behavior is common and temper tantrums occurred in 88% of the
individuals aged between 4-16 years old, but the severity of these problems range
widely.<xref ref-type="bibr" rid="B31">
<sup>31</sup>
</xref>
</p>
<p>Studies suggest a strong association between PWS and atypical psychosis. These
episodes were generally of sudden onset and often included depressive features with
good response to pharmacotherapy and hospitalization.<xref ref-type="bibr" rid="B32">
<sup>32</sup>
</xref>
</p>
<p>Repetitive and ritualistic behavior found in PWS individuals may differ from that
seen in Obsessive-Compulsive Disorder, but may have similarities with the Autism
Spectrum Disorder (ASD) characteristics.<xref ref-type="bibr" rid="B33">
<sup>33</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B34">
<sup>34</sup>
</xref> The denomination ‘autistic-like symptomatology’ may be appropriate when
referring to PWS compulsive behavior and lack of social skills.<xref ref-type="bibr" rid="B33">
<sup>33</sup>
</xref>
</p>
<p>The use of intranasal oxytocin for controlling PWS behavior has come as a possibility
of treatment for these patients, but the benefits and risks are still unkown.<xref ref-type="bibr" rid="B35">
<sup>35</sup>
</xref>
</p>
</sec>
<sec>
<title>OTHER MANIFESTATIONS</title>
<sec>
<title>Sleep Disorders</title>
<p>Sleep disoders are frequently associated with PWS. Excessive daytime sleepiness
(EDS) is the most common condition, followed by obstructive sleep apnea and
narcolepsy-like symptoms. Obesity and hypothalamic dysfunction can, together, be
responsible for the primary abnormalities of ventilation during sleep and
determine the symptoms of EDS.<xref ref-type="bibr" rid="B36">
<sup>36</sup>
</xref>
</p>
<p>In PWS individuals, unlike the general population, the EDS is not fully explained
by the obstructive sleep apnea syndrome.</p>
<p>EDS and REM sleep disorders together are described in narcolepsy syndrome. In
PWS, these narcoleptic symptoms are mainly owed to hypothalamic dysfunction,
once the genetic traces of classic narcolepsy syndrome are not found in
PWS.<xref ref-type="bibr" rid="B37">
<sup>37</sup>
</xref>
</p>
<p>Full night polysomnography studies are recommended in children with abnormal
weight gain, snoring, and appearance of daytime symptoms or poor school
performance.<xref ref-type="bibr" rid="B36">
<sup>36</sup>
</xref> The follow-up of sleep issues on PWS patients can be performed by means
of well-established sleep-related questionnaires, in order to look for specific
sleep disorders.</p>
<p>EDS can be treated with central nervous system stimulants, such as
methylphenidate or modafinil, after complete clinical evaluation. Obstructive
sleep apnea should be treated with oral appliances, continuous or bi-level
positive airway pressure devices (CPAP or BiPAP) or tonsil surgery.</p>
</sec>
<sec>
<title>Scoliosis</title>
<p>Scoliosis is frequently observed in children with PWS, with prevalence between 30
and 70%. Such high frequency may be partly explained by hypotonia and
obesity.<xref ref-type="bibr" rid="B38">
<sup>38</sup>
</xref> There are two peak ages for scoliosis in children with PWS. The presence
of scoliosis under the age of 4 is most likely related to hypotonia, and the
second peak, around 10 years of age, is typically idiopathic.</p>
<p>The earlier the change in the spinal curve is detected, the better the
possibilities of treatment with casting or surgical treatment. This is indicated
in severe early-onset scoliosis-kyphosis and in adolescents near skeletal
maturity. Surgical complications are the risk of paraplegia (20%) and other
major problems (30% of deep infections, pneumonia, hook out).<xref ref-type="bibr" rid="B39">
<sup>39</sup>
</xref>
</p>
</sec>
<sec>
<title>Gastrointestinal Disorders</title>
<p>There are only few studies investigating the gastrointestinal function of
individuals with PWS. Some studies have found either normal or slow gastric
emptying in PWS. Serious events with gastric rupture and necrosis followed by
death have been reported and may be attributed to slow gastric emptying and
absence of vomit.<xref ref-type="bibr" rid="B40">
<sup>40</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B41">
<sup>41</sup>
</xref>
</p>
<p>The incidence of constipation is around 40% in adult PWS patients, which is
considerably higher than reported in the general population. They also have an
increased prevalence of palpable stool in the rectum and prolonged
gastrointestinal transit time.<xref ref-type="bibr" rid="B42">
<sup>42</sup>
</xref>
</p>
</sec>
<sec>
<title>Coagulation Disorders</title>
<p>Although thromboembolic events (TEs) have been recently reported in patients with
PWS, there is no specific guideline for prophylaxis of TEs in this population of
patients. We recommend that inpatients should be evaluated for risk of TE and
receive mechanical prophylaxis (early end frequent ambulation, compression
stockings, intermittent pneumatic compression devices and venous foot pumps),
because they counteract most of the components of the Virchow’s triad and are
not associated with any risk of bleeding. Combined mechanical and
pharmacological prophylaxis should be considered only in PWS patients with high
risk of TEs.</p>
</sec>
<sec>
<title>Dental issues </title>
<p>Dental problems are very common in PWS. PWS individuals have shown reduction in
salivary flow rate and increase in the amounts of salivary ions and proteins.
They present with thick saliva which sticks to the teeth and harbors bacteria
that cause tooth decay and periodontal disease.<xref ref-type="bibr" rid="B43">
<sup>43</sup>
</xref>
</p>
</sec>
</sec>
<sec>
<title>RECOMMENDATIONS</title>
<p>The treatment provided in the Department of Pediatric Endocrinology of the Children’s
Institute of Universidade de São Paulo for these patients is based on a follow-up
protocol with four main pillars: diet (<xref ref-type="fig" rid="f2">Figure
1</xref>), exercise, rhGH use and behavioral and cognitive issues, highlighted on
<xref ref-type="table" rid="t4">Table 2</xref> and on a health maintenance
timeline for children with PWS (<xref ref-type="table" rid="t3">Table 1</xref>)</p>
<p>
<table-wrap id="t4" orientation="portrait" position="float"><label>Table 2:</label><caption><title>Treatment pillars of children with Prader-Willi Syndrome.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Diet Plan</th><th align="center" colspan="1" rowspan="1">GH Therapy</th><th align="center" colspan="1" rowspan="1">Exercise Plan</th><th align="center" colspan="1" rowspan="1">Behavioral and Cognitive Strategies</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Start with a 900 calories/day diet; some patients
may need only 200-650 calories</td><td align="center" colspan="1" rowspan="1">Start at 3 months old</td><td align="center" colspan="1" rowspan="1">1-2 hour of daily exercise </td><td align="center" colspan="1" rowspan="1">Make sure they understand what is said:
expectations and rules.</td></tr><tr><td align="left" colspan="1" rowspan="1">Restrict portions, according to the Prader-Willi
eating pyramid (see figure 1)</td><td align="center" colspan="1" rowspan="3">It is not necessary to take the GH
stimulation test or any other exam before the age of 4 (if there
are no respiratory issues. After this age, a polysomnography is
required)</td><td align="center" colspan="1" rowspan="1">Focus on Aerobic, Resistance and Strength</td><td align="center" colspan="1" rowspan="1">Use verbal and other cues (timers, schedules with
photographs)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ketogenic diet could be an option in patients who
don’t lose weight</td><td align="center" colspan="1" rowspan="2">Working core muscles</td><td align="center" colspan="1" rowspan="1">Literally can foster misunderstandings and
resentment.</td></tr><tr><td align="left" colspan="1" rowspan="1">Anxiety and compulsion control</td><td align="center" colspan="1" rowspan="1">Be realistic in terms of expectations of homework
and class work</td></tr><tr><td align="left" colspan="1" rowspan="3">“No doubt, no hope, no disappointment”
(use of timetables for meals)</td><td align="center" colspan="1" rowspan="2">Initial Dose of 0.5
mg/m<sup>2</sup>/day and maintenance of 1
mg/m<sup>2</sup>/day</td><td align="center" colspan="1" rowspan="3">Improving hypotonia</td><td align="center" colspan="1" rowspan="1">Use n-acetilcistein for skin picking (200-1200
mg/day)</td></tr><tr><td align="center" colspan="1" rowspan="1">Be direct/ Be concrete</td></tr><tr><td align="center" colspan="1" rowspan="1">Adulthood: Dose 0.5 mg/day</td><td align="center" colspan="1" rowspan="1">Compulsiveness/aggressiveness: may need a
psychiatry evaluation</td></tr></tbody></table></table-wrap>
</p>
<p>
<fig id="f2" orientation="portrait" position="float"><label>Figure 1:</label><caption><title>The Prader-Willi eating pyramid is divided into 5 groups: in the
base, there is the vegetable group (6-8 portions a day). Above the
vegetables there is the group of bread, cereal, rice and pasta group
(3-5 portions a day), and next to it is the fruit group (4 portions a
day). The milk, yogurt and cheese group (2 portions a day) stands right
next to meat, poultry, fish, dry beans and egg group (1-2 portions a
day). On the top of the pyramid there are fat and sweets, which should
be eaten only sporadically (<italic>reproduction of the figure was
authorized by www.pwsausa.org</italic>).<xref ref-type="bibr" rid="B44">
<sup>45</sup>
</xref>
</title></caption><graphic xlink:href="0103-0582-rpp-36-03-345-gf1"></graphic></fig>
</p>
</sec>
<sec sec-type="conclusions">
<title>CONCLUSION</title>
<p>The Prader-Willi Syndrome is rare genetic disease, even though it is the main genetic
cause of obesity in children. Early diagnosis can prevent complications and improve
quality of care throughout life. The treatment focuses on four main pillars: diet,
exercise, rhGH therapy and behavioral strategies. </p>
<p>If the general pediatrician becomes more familiar with PWS, the diagnosis will have a
higher probability to take place and, so, treatment will start earlier. This may
improve the quality of life and care for these individuals.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supported-by" id="fn3">
<p>Funding: This study did not receive funding.</p>
</fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griggs</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Sinnayah</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mathai</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome: From genetics to behaviour, with special
focus on appetite treatments</article-title>
<source/>Neurosci Biobehav Rev
          <year>2015</year>
<volume>59</volume>
<fpage>155</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="pmid">26475993</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lionti</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>White</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Rowell</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>A population-based profile of 160 Australians with Prader-Willi
syndrome: trends in diagnosis, birth prevalence and birth
characteristics</article-title>
<source/>Am J Med Genet A
          <year>2015</year>
<volume>167A</volume>
<fpage>371</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="pmid">25424396</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunay-Aygun</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heeger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>O'Riordan</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cassidy</surname>
<given-names>SB</given-names>
</name>
</person-group>
<article-title>The changing purpose of Prader-Willi syndrome clinical diagnostic
criteria and proposed revised criteria</article-title>
<source/>Pediatrics
          <year>2001</year>
<volume>108</volume>
<elocation-id>E92</elocation-id>
<pub-id pub-id-type="pmid">11694676</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holm</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Cassidy</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Hanchett</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Greenswag</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Whitman</surname>
<given-names>BY</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome: consensus diagnostic
criteria</article-title>
<source/>Pediatrics
          <year>1993</year>
<volume>91</volume>
<fpage>398</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="pmid">8424017</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varela</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Setian</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Koiffmann</surname>
<given-names>CP</given-names>
</name>
</person-group>
<article-title>Impact of molecular mechanisms, including deletion size, on
Prader-Willi syndrome phenotype: study of 75 patients</article-title>
<source/>Clin Genet
          <year>2005</year>
<volume>67</volume>
<fpage>47</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">15617548</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saitoh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Buiting</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cassidy</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Conroy</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Driscoll</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Gabriel</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Clinical spectrum and molecular diagnosis of Angelman and
Prader-Willi syndrome patients with an imprinting mutation</article-title>
<source/>Am J Med Genet
          <year>1997</year>
<volume>68</volume>
<fpage>195</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">9028458</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Approach to the child with Prader-Willi Syndrome</article-title>
<source/>J Clin Endocrinol Metab
          <year>2012</year>
<volume>97</volume>
<fpage>3837</fpage>
<lpage>3844</lpage>
<pub-id pub-id-type="pmid">23129592</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rice</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Einfeld</surname>
<given-names>SL</given-names>
</name>
</person-group>
<article-title>Cognitive and behavioural aspects of Prader-Willi
syndrome</article-title>
<source/>Curr Opin Psychiatry
          <year>2015</year>
<volume>28</volume>
<fpage>102</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="pmid">25599341</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bridges</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>What is the value of growth hormone therapy in Prader Willi
syndrome?</article-title>
<source/>Arch Dis Child
          <year>2014</year>
<volume>99</volume>
<fpage>166</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">24162007</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakker</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Kuppens</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Siemensma</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Wijngaarden</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Festen</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Bindels-de Heus</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Eight years of growth hormone treatment in children with
Prader-Willi Syndrome: maintaining the positive effects</article-title>
<source/>J Clin Endocrinol Metab
          <year>2013</year>
<volume>98</volume>
<fpage>4013</fpage>
<lpage>4022</lpage>
<pub-id pub-id-type="pmid">24001750</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colmenares</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Taupin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Giuseppe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Odent</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Trivin</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Effects on growth and metabolism of growth hormone treatment for
3 years in 36 children with Prader-Willi Syndrome</article-title>
<source/>Horm Res Paediatr
          <year>2011</year>
<volume>75</volume>
<fpage>123</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="pmid">20847547</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siemensma</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Wijngaarden</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Festen</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Troeman</surname>
<given-names>ZC</given-names>
</name>
<name>
<surname>Velden</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Otten</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Beneficial effects of growth hormone treatment on cognition in
children with Prader-Willi syndrome: a randomized controlled trial and
longitudinal study</article-title>
<source/>J Clin Endocrinol Metab
          <year>2012</year>
<volume>97</volume>
<fpage>2307</fpage>
<lpage>2314</lpage>
<pub-id pub-id-type="pmid">22508707</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Festen</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Wevers</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lindgren</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Böhm</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Otten</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Wit</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Mental and motor development before and during growth hormone
treatment in infants and toddlers with Prader-Willi syndrome</article-title>
<source/>Clin Endocrinol (Oxf)
          <year>2008</year>
<volume>68</volume>
<fpage>919</fpage>
<lpage>925</lpage>
<pub-id pub-id-type="pmid">18031326</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dykens</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Roof</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hunt-Hawkins</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Cognitive and adaptive advantages of growth hormone treatment in
children with Prader-Willi syndrome</article-title>
<source/>J Child Psychol Psychiatry
          <year>2017</year>
<volume>58</volume>
<fpage>6474</fpage>
<lpage>6474</lpage>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schmoll</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>WV</given-names>
</name>
</person-group>
<article-title>Effects of growth hormone treatment in adults with Prader-Willi
Syndrome</article-title>
<source/>Growth Horm IGF Res
          <year>2013</year>
<volume>23</volume>
<fpage>81</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">23433655</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuppens</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Siemensma</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Wijngaarden</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Donze</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Festen</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Beneficial effects of growth hormone in young adults with
Prader-Willi syndrome: a 2-year cross-over trial</article-title>
<source/>J Clin Endocrinol Metab
          <year>2016</year>
<volume>101</volume>
<fpage>4110</fpage>
<lpage>4116</lpage>
<pub-id pub-id-type="pmid">27552545</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>Canadian Agency for Drugs and Technologies in Health</collab>
</person-group>
<source/>Human growth hormone Treatment for Prader-Willi Syndrome in adolescent
and adult patients: clinical evidence, safety, and guidelines
          <year>2015</year>
<publisher-loc>Ottawa</publisher-loc>
<publisher-name>Canadian Agency for Drugs and Technologies in
Health</publisher-name>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijngaarden</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Otten</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Festen</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Joosten</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Jong</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Sweep</surname>
<given-names>FC</given-names>
</name>
</person-group>
<article-title>High prevalence of central adrenal insufficiency in patients with
Prader-Willi syndrome</article-title>
<source/>J Clin Endocrinol Metab
          <year>2008</year>
<volume>93</volume>
<fpage>1649</fpage>
<lpage>1654</lpage>
<pub-id pub-id-type="pmid">18303077</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharkia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Michaud</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Berthier</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Giguère</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Deladoëy</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Thyroid function from birth to adolescence in Prader-Willi
syndrome</article-title>
<source/>J Pediatr
          <year>2013</year>
<volume>163</volume>
<fpage>800</fpage>
<lpage>805</lpage>
<pub-id pub-id-type="pmid">23623517</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eldar-Geva</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Benarroch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rubistein</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Gross-Tsur</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Hypogonadism in females with Prader-Willi syndrome from infancy
to adulthood: variable combinations of a primary gonadal defect and
hypothalamic dysfunction</article-title>
<source/>Eur J Endocrinol
          <year>2010</year>
<volume>162</volume>
<fpage>377</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="pmid">19946044</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstone</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome: advances in genetics, pathophysiology and
treatment</article-title>
<source/>Trends Endocrinol Metab
          <year>2004</year>
<volume>15</volume>
<fpage>12</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">14693421</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinton</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Gellatly</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Soni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ghatei</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Neural representations of hunger and satiety in Prader-Willi
syndrome</article-title>
<source/>Int J Obes (Lond)
          <year>2006</year>
<volume>30</volume>
<fpage>313</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="pmid">16276365</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parigi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tschop</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heiman</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Salbe</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Vozarova</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sell</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>High circulating ghrelin a potential cause for hyperphagia and
obesity in Prader-Willi syndrome</article-title>
<source/>J Clin Endocrinol Metab
          <year>2002</year>
<volume>87</volume>
<fpage>5461</fpage>
<lpage>5464</lpage>
<pub-id pub-id-type="pmid">12466337</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Azen</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Mittelman</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Geffner</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Jeandron</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Effects of exenatide on weight and appetite in overweight
adolescents and young adults with Prader-Willi syndrome</article-title>
<source/>Pediatr Obes
          <day>13</day>
<month>4</month>
<year>2016</year>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheimann</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Gourash</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cuffari</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Klish</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Critical analysis of bariatric procedures in Prader-Willi
Syndrome</article-title>
<source/>J Pediatr Gastroenterol Nutr
          <year>2008</year>
<volume>46</volume>
<fpage>80</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">18162838</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diene</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mimoun</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Feigerlova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Caula</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Molinas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Grandjean</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Endocrine disorders in children with Prader-Willi syndrome - data
from 142 children of the French database</article-title>
<source/>Horm Res Paediatr
          <year>2010</year>
<volume>74</volume>
<fpage>121</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="pmid">20395666</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fintini</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Grugni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bocchini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brufani</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Di Candia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Corrias</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Disorders of glucose metabolism in Prader-Willi syndrome: Results
of a multicenter Italian cohort study</article-title>
<source/>Nutr Metab Cardiovasc Dis
          <year>2016</year>
<volume>26</volume>
<fpage>842</fpage>
<lpage>847</lpage>
<pub-id pub-id-type="pmid">27381990</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dykens</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Hodapp</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Nash</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>Profiles, correlates, and trajectories of intelligence in
Prader-Willi syndrome</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>1992</year>
<volume>31</volume>
<fpage>1125</fpage>
<lpage>1130</lpage>
<pub-id pub-id-type="pmid">1429416</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lukoshe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hokken-Koelega</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Lugt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>White</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Reduced cortical complexity in children with Prader-Willi
Syndrome and its association with cognitive impairment and developmental
delay</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<elocation-id>e107320</elocation-id>
<pub-id pub-id-type="pmid">25226172</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kates</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Ikuta</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Burnette</surname>
<given-names>CP</given-names>
</name>
</person-group>
<article-title>Gyrification patterns in monozygotic twin pairs varying in
discordance for autism</article-title>
<source/>Autism Res
          <year>2009</year>
<volume>2</volume>
<fpage>267</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="pmid">19890876</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dykens</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Psychiatric disorders in Prader-Willi syndrome epidemiology and
management</article-title>
<source/>CNS Drugs
          <year>2003</year>
<volume>17</volume>
<fpage>167</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="pmid">12617696</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome and psychoses</article-title>
<source/>Br J Psychiatry
          <year>1993</year>
<volume>163</volume>
<fpage>680</fpage>
<lpage>684</lpage>
<pub-id pub-id-type="pmid">8298842</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimitropoulos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>RT</given-names>
</name>
</person-group>
<article-title>Autistic-like symptomatology in Prader-Willi syndrome: a review
of recent findings</article-title>
<source/>Curr Psychiatry Rep
          <year>2007</year>
<volume>9</volume>
<fpage>159</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="pmid">17389128</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaves</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Prince</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Charman</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Repetitive and ritualistic behaviour in children with
Prader-Willi syndrome and children with autism</article-title>
<source/>J Intellect Disabil Res
          <year>2006</year>
<volume>50</volume>
<fpage>92</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">16403198</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuppens</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Donze</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Hokken-Koelega</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Promising effects of oxytocin on social and food-related
behaviour in young children with Prader-Willi Syndrome a randomized,
double-blind, controlled crossover trial</article-title>
<source/>Clin Endocrinol (Oxf)
          <year>2016</year>
<volume>85</volume>
<fpage>979</fpage>
<lpage>987</lpage>
<pub-id pub-id-type="pmid">27486141</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruni</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Verrillo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Novelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ferri</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome: sorting out the relationships between
obesity, hypersomnia, and sleep apnea</article-title>
<source/>Curr Opin Pulm Med
          <year>2010</year>
<volume>16</volume>
<fpage>568</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="pmid">20814307</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camfferman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McEvoy</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>O'Donoghue</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lushington</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Prader Willi Syndrome and excessive daytime
sleepiness</article-title>
<source/>Sleep Med Rev
          <year>2008</year>
<volume>12</volume>
<fpage>65</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">18201664</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijngaarden</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Klerk</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Festen</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Hokken-Koelega</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Scoliosis in Prader-Willi syndrome: prevalence, effects of age,
gender, body mass index, lean body mass and genotype</article-title>
<source/>Arch Dis Child
          <year>2008</year>
<volume>93</volume>
<fpage>1012</fpage>
<lpage>1016</lpage>
<pub-id pub-id-type="pmid">18263693</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kroonen</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pizzutillo</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Macewen</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>Prader-Willi Syndrome: clinical concerns for the orthopaedic
surgeon</article-title>
<source/>J Pediatr Orthop
          <year>2006</year>
<volume>26</volume>
<fpage>673</fpage>
<lpage>679</lpage>
<pub-id pub-id-type="pmid">16932110</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arenz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schwarzer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pfluger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Koletzko</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Schmidt H: Delayed gastric emptying in patients with Prader Willi
Syndrome</article-title>
<source/>J Pediatr Endocrinol Metab
          <year>2010</year>
<volume>23</volume>
<fpage>867</fpage>
<lpage>871</lpage>
<pub-id pub-id-type="pmid">21175084</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevenson</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Heinemann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Angulo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Loker</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rupe</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Gastric rupture and necrosis in Prader-Willi
syndrome</article-title>
<source/>J Pediatr Gastroenterol Nutr
          <year>2007</year>
<volume>45</volume>
<fpage>272</fpage>
<lpage>274</lpage>
<pub-id pub-id-type="pmid">17667731</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhlmann</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Joensson</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Froekjaer</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Krogh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Farholt</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A descriptive study of colorectal function in adults with
Prader-Willi Syndrome: high prevalence of constipation</article-title>
<source/>BMC Gastroenterol
          <year>2014</year>
<volume>14</volume>
<fpage>63</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">24708524</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hart</surname>
<given-names>PS</given-names>
</name>
</person-group>
<article-title>Salivary abnormalities in Prader-Willi syndrome</article-title>
<source/>Ann N Y Acad Sci
          <year>1998</year>
<volume>842</volume>
<fpage>125</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="pmid">9599302</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="webpage">
<person-group person-group-type="author">
<collab>Pwsausa.org</collab>
</person-group>
<comment>homepage on the internet</comment>
<source/>USA Prader Willi Syndrome Association
          <date-in-citation content-type="access-date" iso-8601-date="2016-11-16">2016 Nov
16</date-in-citation>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.pwsausa.org/">http://www.pwsausa.org/</ext-link></comment>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>